0001104659-24-028472.txt : 20240228 0001104659-24-028472.hdr.sgml : 20240228 20240228073520 ACCESSION NUMBER: 0001104659-24-028472 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240228 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 24690190 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 8-K 1 tm247423d1_8k.htm FORM 8-K
false 0001730430 0001730430 2024-02-28 2024-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 28, 2024

 

Kiniksa Pharmaceuticals, Ltd.

(Exact name of Registrant as Specified in Its Charter)

 

Bermuda   001-730430   98-1327726
(State or other jurisdiction of
incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

Kiniksa Pharmaceuticals, Ltd.

Clarendon House

2 Church Street

Hamilton HM11, Bermuda
(808) 451-3453

(Address, zip code and telephone number, including area code of principal executive offices)

 

Kiniksa Pharmaceuticals Corp.

100 Hayden Avenue

Lexington, MA, 02421

(781) 431-9100

(Address, zip code and telephone number, including area code of agent for service)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on which
registered
Class A Common Shares $0.000273235 par value   KNSA   The Nasdaq Stock Market LLC
        (Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On February 28, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

 

The information contained in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Description
     
99.1   Q4 and FY2023 Earnings Press Release issued by Kiniksa Pharmaceuticals, Ltd. dated February 28, 2024
     
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  KINIKSA PHARMACEUTICALS, LTD.
   
Date: February 28, 2024 By: /s/ Madelyn Zeylikman
    Madelyn Zeylikman
    Senior Vice President, General Counsel and Secretary

 

 

 

 EX-99.1 2 tm247423d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

 

– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –

 

– ARCALYST 2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint –

 

– Abiprubart Phase 2 rheumatoid arthritis data from Cohort 4 and a new development indication expected in April 2024 –

 

– Cash reserves of $206.4 million expected to fund operations into at least 2027 –

 

– Conference call and webcast scheduled for 8:30 am ET today –

 

HAMILTON, BERMUDA – February 28, 2024 – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2023 financial results and recent portfolio execution.

 

“Kiniksa meaningfully advanced its business in 2023, primarily through robust ARCALYST net product revenue and collaboration profit growth. Significant growth remains with ARCALYST in recurrent pericarditis, and we expect to help an increasing number of patients in the years ahead. Importantly, we anticipate our robust commercial performance to contribute to our strong financial position and ability to drive growth across our business,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Additionally, abiprubart recently showed clinical effect in the first three cohorts of the Phase 2 trial in rheumatoid arthritis. We now expect to advance the asset into a Phase 2b trial in a new indication, funding for which is included in our current cash runway guidance. Data from the fourth cohort of the abiprubart Phase 2 trial are intended to inform trial design and are expected in April.”

 

Portfolio and Collaboration Execution

 

ARCALYST (IL-1α and IL-1β cytokine trap)

 

•ARCALYST net product revenue was $71.2 million and $233.2 million for the fourth quarter and full-year 2023, respectively.

 

1

 

 

•Since launch in April 2021, more than 1,700 prescribers have written ARCALYST prescriptions for recurrent pericarditis.

 

•As of the end of the fourth quarter of 2023, average total duration of ARCALYST therapy in recurrent pericarditis had increased to approximately 23 months.

 

•As of the end of the fourth quarter of 2023, approximately 9% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.

 

•A poster entitled Rilonacept Utilization in a Steroid-Sparing Paradigm for Recurrent Pericarditis: Real-World Evidence Demonstrating Increased Adoption is planned to be presented at the upcoming American College of Cardiology Scientific Session (ACC.24) in April 2024.

 

Abiprubart (anti-CD40 monoclonal antibody inhibitor of CD40-CD154 interaction)

 

•Kiniksa previously announced topline data from the Phase 2 clinical trial of abiprubart in rheumatoid arthritis, showing that the trial met its primary efficacy endpoint: change from baseline in Disease Activity Score of 28 Joints Using C-reactive Protein (DAS28-CRP) versus placebo.

 

—In Cohorts 1 and 2 (pharmacokinetic lead-in), multiple doses of abiprubart were well-tolerated.

 

—In Cohort 3, the abiprubart 5 mg/kg subcutaneous (SC) weekly dose level achieved statistical significance. The 5 mg/kg SC biweekly dose level did not achieve statistical significance. Across both dose levels abiprubart reduced Rheumatoid Factor, a clinical marker of disease activity and an autoantibody pharmacodynamic marker of CD40 target engagement. Abiprubart was well-tolerated, with no dose-related adverse experiences observed.

 

•Kiniksa expects data from the fourth cohort (Cohort 4) of the Phase 2 clinical trial in April 2024. Cohort 4 will evaluate a fixed dose level administered as a single subcutaneous injection once monthly.

 

Mavrilimumab (monoclonal antibody inhibitor targeting GM-CSFRα)

 

•Kiniksa is evaluating potential partnership opportunities to advance development of mavrilimumab, which has generated positive data in mid-stage clinical trials across multiple indications.

 

Vixarelimab (monoclonal antibody inhibitor of signaling through OSMRβ)

 

•In the fourth quarter of 2023, Kiniksa recognized a $10.0 million development milestone related to a second new indication under its global license agreement with Genentech, a member of the Roche Group.

 

Financial Results

 

•Total revenue for the fourth quarter of 2023 was $83.4 million, compared to $61.9 million for the fourth quarter of 2022. Total revenue for the full-year 2023 was $270.3 million, compared to $220.2 million for the full-year 2022.

 

2

 

 

—Total revenue for the fourth quarter of 2023 included $12.2 million in license and collaboration revenue, compared to $21.9 million for the fourth quarter of 2022.

 

—Total revenue for the full-year 2023 included $37.1 million in license and collaboration revenue, compared to $97.7 million for the full-year 2022.

 

•Total operating expenses for the fourth quarter of 2023 were $83.3 million, compared to $55.8 million for the fourth quarter of 2022. Total operating expenses for the full-year 2023 were $295.5 million, compared to $210.4 million for the full-year 2022.

 

—Total operating expenses for the fourth quarter of 2023 included $16.9 million in collaboration expenses, which are driven by ARCALYST collaboration profitability, compared to $7.5 million for the fourth quarter of 2022. Total operating expenses for the full-year 2023 included $56.5 million in collaboration expenses, compared to $24.1 million for the full-year 2022.

 

—Total operating expenses for the fourth quarter of 2023 included $7.8 million in non-cash, share-based compensation expense, compared to $6.4 million for the fourth quarter of 2022. Total operating expense for the full-year 2023 included $27.1 million in non-cash, share-based compensation expense, compared to $25.1 million for the full-year 2022.

 

•Net income for the fourth quarter of 2023 was $25.2 million, compared to net income of $4.5 million for the fourth quarter of 2022. Net income for the full-year 2023 was $14.1 million, compared to net income of $183.4 million for the full-year 2022.

 

—Net income for the fourth quarter of 2023 included a tax benefit of $22.8 million, primarily due to the treatment of non-cash deferred tax assets, compared to a tax expense of $2.4 million for the fourth quarter of 2022.

 

—Net income for the full-year 2023 included a tax benefit of $30.7 million, compared to a tax benefit of $172.3 million for the full-year 2022, both primarily due to the treatment of non-cash deferred tax assets.

 

•As of December 31, 2023, Kiniksa had $206.4 million of cash, cash equivalents, and short-term investments and no debt.

 

Financial Guidance

 

•Kiniksa expects 2024 ARCALYST net product revenue of between $360 million and $380 million.

 

•Kiniksa expects that its cash, cash equivalents, and short-term investments will fund its current operating plan into at least 2027.

 

Conference Call Information

 

•Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results and recent portfolio execution.

 

•Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

 

3

 

 

About Kiniksa

 

Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

 

About ARCALYST
ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

 

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST

 

•ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).

 

•While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.

 

•Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.

 

•Medicines that affect the immune system may increase the risk of getting cancer.

 

•Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.

 

•Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.

 

4

 

 

•Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

 

For more information about ARCALYST, talk to your doctor and see the Product Information.

 

About Abiprubart

 

Abiprubart is an investigational humanized monoclonal antibody that binds to CD40 and is designed to inhibit the CD40-CD154 (CD40 ligand) interaction, a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching and Type 1 immune responses. Kiniksa believes disrupting the CD40-CD154 co-stimulatory interaction is an attractive approach to addressing multiple autoimmune disease pathologies.

 

About Mavrilimumab

 

Mavrilimumab is an investigational fully human monoclonal antibody that blocks activity of GM-CSF by specifically binding to the alpha subunit of the GM-CSF receptor (GM-CSFRα). Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved their primary and secondary endpoints with statistical significance. Kiniksa is evaluating potential partnership opportunities for mavrilimumab.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST 2024 net product revenue will be between $360 million and $380 million; our plan to report data from Cohort 4 of our Phase 2 clinical trial of abiprubart in rheumatoid arthritis and a new development indication for abiprubart in April 2024; our expectation about our cash reserves funding our current operating plan into at least 2027; our expectation that we will help an increasing number of patients in the future; our plan to develop abiprubart in an additional indication; our plan to present a poster at the upcoming American College of Cardiology Scientific Session in April 2024; our beliefs about the mechanisms of our product candidates and potential impact of their approach, including that using abiprubart to disrupt the CD40-CD154 co-stimulatory interaction is an attractive approach to address multiple autoimmune disease pathologies; and our belief that all of our product candidates offer the potential for differentiation.

 

5

 

 

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; inability to successfully execute on our commercial strategy for ARCALYST; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; our reliance on Regeneron as the current sole manufacturer of ARCALYST; risks arising from our ongoing technology transfer of ARCALYST drug substance manufacturing; raw material, important ancillary product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; changes in our operating plan, business development strategy or funding requirements; and existing or new competition.

 

These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 

ARCALYST® is a registered trademark of Regeneron. All other trademarks are the property of their respective owners.

 

Every Second Counts! ®

 

Kiniksa Investor and Media Contact

Rachel Frank

(339) 970-9437

rfrank@kiniksa.com

 

6

 

 

KINIKSA PHARMACEUTICALS, LTD.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

 

   Three Months Ended   Years Ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
Revenue:                    
Product revenue, net  $71,220   $39,939   $233,176   $122,524 
License and collaboration revenue   12,175    21,945    37,083    97,656 
Total revenue   83,395    61,884    270,259    220,180 
Operating expenses:                    
Cost of goods sold   9,584    6,710    33,407    22,895 
Collaboration expenses   16,939    7,522    56,524    24,071 
Research and development   20,052    14,390    76,097    65,490 
Selling, general and administrative   36,739    27,215    129,427    97,951 
Total operating expenses   83,314    55,837    295,455    210,407 
Income (loss) from operations   81    6,047    (25,196)   9,773 
Other income   2,369    794    8,544    1,253 
Income (loss) before income taxes   2,450    6,841    (16,652)   11,026 
Benefit (provision) for income taxes   22,787    (2,380)   30,736    172,337 
Net income  $25,237   $4,461   $14,084   $183,363 
Net income per share attributable to common shareholders—basic  $0.36   $0.06   $0.20   $2.64 
Net income per share attributable to common shareholders—diluted   0.35    0.06    0.20    2.60 
Weighted average common shares outstanding—basic   70,371,601    69,609,342    70,058,952    69,382,275 
Weighted average common shares outstanding—diluted   72,660,171    71,369,394    71,922,915    70,421,322 

 

KINIKSA PHARMACEUTICALS, LTD.

SELECTED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

(Unaudited)

 

   As of 
   December 31,   December 31, 
   2023   2022 
Cash, cash equivalents, and short-term investments  $206,371   $190,608 
Working capital   212,631    195,994 
Total assets   526,322    459,672 
Accumulated deficit   (477,950)   (492,034)
Total shareholders' equity   438,839    396,149 

 

7

 EX-101.SCH 3 knsa-20240228.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 knsa-20240228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 knsa-20240228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm247423d1_ex99-1img001.jpg GRAPHIC begin 644 tm247423d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 28, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 28, 2024
Entity File Number 001-730430
Entity Registrant Name Kiniksa Pharmaceuticals, Ltd.
Entity Central Index Key 0001730430
Entity Tax Identification Number 98-1327726
Entity Incorporation, State or Country Code D0
Entity Address, Address Line One Clarendon House
Entity Address, Address Line Two 2 Church Street
Entity Address, City or Town Hamilton
Entity Address, Country BM
Entity Address, Postal Zip Code HM11
City Area Code 808
Local Phone Number 451-3453
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Shares $0.000273235 par value
Trading Symbol KNSA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://kiniksa.com/role/Cover Cover Cover 1 false false All Reports Book All Reports knsa-20240228.xsd knsa-20240228_lab.xml knsa-20240228_pre.xml tm247423d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm247423d1_8k.htm": { "nsprefix": "knsa", "nsuri": "http://kiniksa.com/20240228", "dts": { "schema": { "local": [ "knsa-20240228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "knsa-20240228_lab.xml" ] }, "presentationLink": { "local": [ "knsa-20240228_pre.xml" ] }, "inline": { "local": [ "tm247423d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://kiniksa.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247423d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247423d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-028472-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-028472-xbrl.zip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tm247423d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001730430 2024-02-28 2024-02-28 iso4217:USD shares iso4217:USD shares false 0001730430 8-K 2024-02-28 Kiniksa Pharmaceuticals, Ltd. D0 001-730430 98-1327726 Clarendon House 2 Church Street Hamilton HM11 BM 808 451-3453 false false false false Class A Common Shares $0.000273235 par value KNSA NASDAQ false